Fecal S100A12 is associated with future hospitalization and step-up of medical treatment in patients with Crohn’s disease in clinical remission: a pilot study

Expert opinion for use of faecal calprotectin in diagnosis and monitoring of inflammatory bowel disease in daily clinical practice

(2018) Catherine Reenaers et al.   United European Gastroenterology Journal

Fecal calprotectin in assessing inflammatory bowel disease endoscopic activity: a diagnostic accuracy meta-analysis

(2018)   Journal of Gastrointestinal and Liver Diseases

Crohn's disease

(2017) Joana Torres et al.   LANCET

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial

(2017) Jean-Frederic Colombel et al.   LANCET

Utility of surrogate markers for the prediction of relapses in inflammatory bowel diseases

(2016) Jason Orlando Dimitri Musci et al.   JOURNAL OF GASTROENTEROLOGY

C-Reactive Protein, Fecal Calprotectin and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis

(2015) Mahmoud H Mosli et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Accuracies of Serum and Fecal S100 Proteins (Calprotectin and Calgranulin C) to Predict the Response to TNF Antagonists in Patients with Crohnʼs Disease

(2015) Gilles Boschetti et al.   INFLAMMATORY BOWEL DISEASES

Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse

(2009) Javier P. Gisbert et al.   INFLAMMATORY BOWEL DISEASES

Phagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease

(2008) D Foell et al.   JOURNAL OF PATHOLOGY

Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children

(2007) Marc A. Sidler et al.   INFLAMMATORY BOWEL DISEASES